Organization | L K Whittier Foundation

L K Whittier Foundation Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial

2013

NCT02067884

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Whittier Foundation

Active Ingredients

Drugs in Phase 1 Trials (4)

cytarabine (cytosar-u) (1 trial)

ephb4-hsa fusion protein (1 trial)

perflutren protein-type a microspheres (Optison) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Myelodysplastic-Myeloproliferative Diseases (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Philadelphia Chromosome (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 2
# of Trial APIs: 4